SUB-TYPE: COMPANY-LED RECALL
Pfizer UK Limited is recalling the below batches. This is because routine stability testing has identified that levels of a known impurity, 10-oxo-docetaxel, may exceed the acceptable level at end of shelf-life.
Please visit the: MHRA website for more details on this drug alert.
The affected products' details are as follows:
PIP Code | Product Description | Supplier | Affected Batch |
---|---|---|---|
8120875 | DOCETAXEL VIAL 20MG PFZ 2ML | PFIZER LTD | S0150518 |
8120867 | DOCETAXEL VIAL 160MG PFZ 16ML | PFIZER LTD | S0390218 S0120218 |
Please do not consolidate any stock for return. All returns must be from the original delivery address. Any product(s) returned from non-Pfizer accounts will be retained by the distribution centre and not returned. Credit for these returned products must be obtained from the supplier from where the product was purchased.
All Stock must be returned to Alliance Healthcare before the 19th September 2019.
For medical information please contact Pfizer Medical Information Department on 01304 616161
Recipients of this Drug Alert should bring it to the attention of relevant contacts.
If you have any questions, then please contact your local Service Centre Customer Services team.
SUB-TYPE: CLASS 2 RECALL
Sandoz Ltd. have been notified of a potential packaging problem relating to poor seal adherence which could cause clumping of the powder within the bottle. A poor bottle seal could lead to degradation of the clavulanic acid within the powder and could potentially render the product ineffective..
Please visit the: MHRA website for more details on this drug alert.
The affected products' details are as follows:
PIP Code | Product Description | Supplier | Affected Batch |
---|---|---|---|
1086271 | CO-AMOXICLAV SF 125/31.25MG | SANDOZ LTD | HT6202 HT7923 |
1117290 | CO-AMOXICLAV 31/125MG/5ML | SANDOZ LTD | HT6202 HT7923 |
1086289 | CO-AMOXICLAV 250/62MG | SANDOZ LTD | HT6202 HT7923 |
1117308 | CO-AMOXICLAV SF 250/62.5MG | SANDOZ LTD | HT6202 HT7923 |
For enquiries relating to stock returns please contact Sandoz Limited Customer Services on 01276 698607 or email sales.sandoz-gb@sandoz.com
For Medical information enquiries, please contact Sandoz Medical Information Team on 01276 698101or email sandozgb@EU.propharmagroup.com
Recipients of this Drug Alert should bring it to the attention of relevant contacts.
Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.
If you have any questions, then please contact your local Service Centre Customer Services team.
SUB-TYPE: CLASS 4 CAUTION IN USE
Genesis Pharmaceuticals Ltd has informed us that there is an error on the Braille for the above batches which means that the strength reads as 1mg instead of 5mg. The printed text is correct on all packaging.
Please visit the: MHRA website for more details on this drug alert
The affected products' details are as follows:
For further information please contact Genesis Pharmaceuticals Ltd, tel. 020 7201 0400.
This is a caution in use only and therefore we are not accepting stock returns.
If you have any questions, then please contact your local Service Centre Customer Services team.
PIP Code | Product Description | Supplier | Affected Batches |
---|---|---|---|
1110840 | PREDNISOLONE TAB 5MG ALM | ALMUS PHARMACEUTICALS LTD | 1809653 1809654 1809655 1809656 1809657 |
1057363 | PREDNISOLONE TAB 5MG ACT | ACCORD SCHEME | 1809653 1809654 1809655 1809656 1809657 |
1057132 | PREDNISOLONE TAB 5MG TEV | TEVA UK LTD | 1809653 1809654 1809655 1809656 1809657 |
1052893 | PREDNISOLONE TAB 5MG CP | WOCKHARDT ETHICAL(MOV) | 1809653 1809654 1809655 1809656 1809657 |
SUB-TYPE: CLASS 2 RECALL
Teva UK Limited and Mylan are recalling some Valsartan containing products including certain batches supplied by Teva UK Limited and all unexpired batches supplied by Mylan.
Please visit the: MHRA website for more details on this drug alert.
The affected products' details are as follows:
PIP Code | Product Description | Livery | Affected Batches |
---|---|---|---|
8466179 | VALSARTAN TAB 40MG | TEVA UK LIMITED | 100350 100938 101776 |
1166909 | VALSARTAN TAB 40MG TEV | TEVA UK LIMITED | 100350 100938 101776 |
1167535 | VALSARTAN TAB 40MG GUK | TEVA UK LIMITED | 100350 100938 101776 |
1161546 | VALSARTAN TAB 40MG ACT | TEVA UK LIMITED | 100350 100938 101776 |
8466245 | VALSARTAN TAB 320MG | TEVA UK LIMITED | 100433 101777 |
1166917 | VALSARTAN TAB 320MG TEV | TEVA UK LIMITED | 100433 101777 |
1173152 | VALSARTAN TAB 320MG ACT | TEVA UK LIMITED | 100433 101777 |
1166958 | VALSARTAN HCTZ TAB80/12.5MG TEV | TEVA UK LIMITED | 6P601163 6P606333 0001584 0002626 0002627 0003214 0004744 |
8466203 | VALSARTAN HCTZ TAB 80MG/12.5MG | TEVA UK LIMITED | 6P601163 6P606333 0001584 0002626 0002627 0003214 0004744 |
1161520 | VALSARTAN HCT TAB 80/12.5MG ACT | TEVA UK LIMITED | 6P601163 6P606333 0001584 0002626 0002627 0003214 0004744 |
8466161 | VALSARTAN HCTZ TAB 160MG/25MG | TEVA UK LIMITED | 6P601084 6P606270 0000350 0000352 0001997 0002338 0003615 |
1166941 | VALSARTAN HCT TAB 160/25MG TEV | TEVA UK LIMITED | 6P601084 6P606270 0000350 0000352 0001997 0002338 0003615 |
1162353 | VALSARTAN HCT TAB 160/25MG ACT | TEVA UK LIMITED | 6P601084 6P606270 0000350 0000352 0001997 0002338 0003615 |
8466195 | VALSARTAN HCTZ TAB 160MG/12.5MG | TEVA UK LIMITED | 6P607166 0000426 0001520 0001521 0002298 0003663 0004670 |
1166966 | VALSARTAN HCT TAB 160/12.5MG TEV | TEVA UK LIMITED | 6P607166 0000426 0001520 0001521 0002298 0003663 0004670 |
1161538 | VALSARTAN HCT TAB 160/12.5MG ACT | TEVA UK LIMITED | 6P607166 0000426 0001520 0001521 0002298 0003663 0004670 |
1167626 | VALSARTAN CAPSULES 80MG ACT | MYLAN | ALL STOCK |
1166883 | VALSARTAN CAP 80MG TEV | MYLAN | ALL STOCK |
8466229 | VALSARTAN CAP 80MG | MYLAN | ALL STOCK |
1166214 | VALSARTAN CAP 80 MG GUK | MYLAN | ALL STOCK |
1166875 | VALSARTAN CAP 40MG TEV | MYLAN | ALL STOCK |
1167618 | VALSARTAN CAP 40MG ACT | MYLAN | ALL STOCK |
8466237 | VALSARTAN CAP 40MG | MYLAN | ALL STOCK |
1166206 | VALSARTAN CAP 40 MG GUK | MYLAN | ALL STOCK |
1166891 | VALSARTAN CAP 160MG TEV | MYLAN | ALL STOCK |
8466211 | VALSARTAN CAP 160MG | MYLAN | ALL STOCK |
1166222 | VALSARTAN CAP 160 MG GUK | MYLAN | ALL STOCK |
1167634 | VALSARTAN CAPSULES 160MG ACT | MYLAN | ALL STOCK |
Teva UK Limited
For stock control: general.enquiries@tevauk.com
For medical information enquiries: medinfo@tevauk.com
Mylan
For stock control: mguk_customer.services@mylan.co.uk, 01707 853100
For medical information enquiries: info@mylan.co.uk, 01707 853 000, Option 1
Any stock returned after the 30th April 2019 will not receive credit.
Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.
If you have any questions, then please contact your local Service Centre Customer Services team.
SUB-TYPE: CLASS 4 CAUTION IN USE
Ranbaxy (UK) Ltd a Sun Pharmaceutical Company, has informed us that some packs from the above batch contain a Patient Information Leaflet (PIL) for Temozolomide 180mg Capsules..
Please visit the: MHRA website for more details on this drug alert.
The affected products' details are as follows:
PIP CodeProduct DescriptionLiveryAffected Batch
1186964Zoledronic acid 5mg solution for infusionRanbaxy (UK) LtdJKT1576A
For any enquiries, please contact Ranbaxy / Sun Pharmaceuticals customer services team: Tel: 020 8848 5050; email: cserv.uk@sunpharma.com.
Recipients of this Drug Alert should bring it to the attention of relevant contacts.
This is a caution in use only and therefore we are not accepting stock returns.
If you have any questions, then please contact your local Service Centre Customer Services team.
SUB-TYPE: CLASS 2 RECALL
Accord Healthcare are recalling all unexpired stock of the above products from pharmacies and wholesalers as a precautionary measure due to possible contamination with an impurity Nnitrosodimethylamine (NDMA) which has genotoxic and carcinogenic potential.
Please visit the: MHRA website for more details on this drug alert.
The affected products' details are as follows:
PIP Code | Product Description | Supplier | Affected Batch |
---|---|---|---|
7056195 | RANITIDINE TAB 150MG | Accord Healthcare | ALL STOCK |
1069087 | RANITIDINE TAB 150MG | Accord Healthcare | ALL STOCK |
7056203 | RANITIDINE TAB 300MG | Accord Healthcare | ALL STOCK |
1069046 | RANITIDINE TAB 300MG | Accord Healthcare | ALL STOCK |
1179191 | RANITIDINE TABS 150MG | Accord Healthcare | ALL STOCK |
For stock control enquiries please contact Accords Customer Service team on 0800 373573
For medical information enquiries please contact Accords Pharmacovigilance Department on 01271 385257 or medinfo@accord-healthcare.com
Recipients of this Drug Alert should bring it to the attention of relevant contacts.
Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.
If you have any questions, then please contact your local Service Centre Customer Services team.
SUB-TYPE: CLASS 2 RECALL
M & A Pharmachem is recalling the above batches as a precautionary measure, because a small number of pots from some batches have been found to contain discoloured tablets due to fungal contamination. The fungus has been identified as Penicillium citrinum. It is unlikely that any affected tablets will have got to patient level as the discolouration is noticeable on opening affected packs.
Please visit the: MHRA website for more details on this drug alert.
The affected products' details are as follows:
PIP Code | Product Description | Supplier | Affected Batch |
---|---|---|---|
7018393 | PARACETAMOL TAB BP 500MG | M&A PHARMACHEM | ALL STOCK |
For enquiries relating to stock returns please contact Pauline Caddick, Responsible Person: pcaddick@mapharmachem.co.uk
For Medical information enquiries, please contact Cristina Parau, Pharmacovigilance Manager: email cparau@mapharmachem.co.uk
Recipients of this Drug Alert should bring it to the attention of relevant contacts.
Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.
If you have any questions, then please contact your local Service Centre Customer Services team.
SUB-TYPE: CLASS 3 RECALL
Sanofi are recalling the listed batches of Taxotere (Docetaxel) Concentrate due to a production fault potentially leading to an increase in the concentration of Docetaxel in the solution.
Please visit the: MHRA website for more details on this drug alert.
The affected products' details are as follows:
PIP Code | Product Description | Supplier | Affected Batch |
---|---|---|---|
3556727 | Taxotere (Docetaxel) Concentrate for Solution for Infusion, 80mg per 4ml | Sanofi UK | 5F219A |
Company contact for all enquiries: Sanofi Medical Information Department on Tel: 0845 3727101 or Email: UK-Medicalinformation@sanofi.com
Recipients of this Drug Alert should bring it to the attention of relevant contacts.
Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.
If you have any questions, then please contact your local Service Centre Customer Services team.
SUB-TYPE: CLASS 3 RECALL
Advancis Medical Ltd are recalling the below batch due to the potential packaging integrity.
Please visit the GOV.UK drug alert link: N/A
The affected products' details are as follows:
PIP Code | Product Description | Supplier | Affected Batch |
---|---|---|---|
3193703 | Algivon Alg Strl Drsg 10cmsq X 5 | Advancis Medical | WO013976 |
Action:
1. Contact our sales team (inese.haqure@brightwake.cauk) to request a Return Goods Number (RGN) so that we can reconcile and replace all potentially affected product.
2. Please return the affected product listed above to receive replacement.
Recipients of this Drug Alert should bring it to the attention of relevant contacts.
Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.
If you have any questions, then please contact your local Service Centre Customer Services team.
SUB-TYPE: CLASS 4 CAUTION IN USE
G.L. Pharma GmbH would like to inform Healthcare professionals that they are aware that there is an error on the carton for batches 5E048A and 5H155A in relation to the strength. Inadvertently, the information "Each capsule contains 150 mg valproic acid." was printed on one side of the cartons instead of the correct "Each capsule contains 500 mg valproic acid." All other information, especially the main headings on the package ("Convulex® capsules 500 mg"), however is correct on the carton. G.L. Pharma GmbH confirms that capsules are 500mg strength. The correct strength is also given on the primary blister pack and the patient information leaflet. G.L. Pharma GmbH have informed the MHRA and the MHRA have approved the continued distribution of batches 5E048A and 5H155A until replacement stock is available.
The affected products' details are as follows:
PIP Code | Product Description | Supplier | Affected Batches |
---|---|---|---|
0560656 | Convulex 500mg Capusles | Pfizer Ltd | 5E048A 5H155A |